529 completed. 529 Phase 2, 61 Phase 3, 55 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 529 | Completed 529 |
| Phase 3 | 61 | Completed 61 |
| Phase 1 | 55 | Completed 55 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients Ropanicant, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Completed | Suven Life Sciences Limited | 214 | 2025-07-15 | 2026-04-07 |
| Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Completed | BioXcel Therapeutics Inc | 33 | 2025-06-19 | 2026-10-05 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray - Major Depressive Disorder (MDD | Phase 2 | Completed | Sichuan Purity Pharmaceutical Technology Co., Ltd. | 98 | 2025-05-27 | 2026-09-09 |
| A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder KH607 tablets, placebo - Major Depressive Disorder (MDD) | Phase 2 | Completed | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 126 | 2025-03-19 | 2026-07-28 |
| A Study of ONO-1110 in Patients With Major Depressive Disorder ONO-1110, Placebo - Major Depressive Disorder (MDD | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 103 | 2025-01-16 | 2026-07-08 |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) VLS-01-203 BU, VLS-01-BU Placebo - Treatment Resistant Depression | Phase 2 | Completed | atai Therapeutics, Inc. | 142 | 2024-12-30 | 2026-10-30 |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder JNJ-89495120, Placebo - Depressive Disorder, Major | Phase 2 | Completed | Janssen Research & Development, LLC | 105 | 2024-12-26 | 2026-09-25 |
| A Phase II Study to Evaluate NH102 for Depression NH102, Duloxetine Hydrochloride Enteric-coated Capsule, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Completed | Jiangsu Nhwa Pharmaceutical Co., Ltd. | 243 | 2024-12-04 | 2026-09-22 |
| Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers Psilocybin, Cognitive Behavioral Therapy (CBT) - Major Depressive Disorder | Phase 2 | Completed | Khyber Medical University Peshawar | 60 | 2024-12-01 | 2025-09-02 |
| FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression Ketamine, Functional magnetic resonance imaging (fMRI) - Bipolar Depression, Treatment Resistant Bipolar Depression | Phase 2 | Completed | Drew Cumming | 20 | 2024-11-12 | 2026-10-15 |
| Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety BMND08, Brain electrical activity monitor, Pharmacokinetic Study of Sublingually Administered Psychoactive Substance - Healthy Volunteers | Phase 1 / Phase 2 | Completed | Biomind Labs Inc. | 40 | 2024-10-21 | 2025-03-05 |
| Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder ABBV-932, Placebo for ABBV-932 - Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Completed | AbbVie | 161 | 2024-10-15 | 2026-10-14 |
| A Study to Test Different Doses of BI 1569912 in People With Depression 5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912 - Depressive Disorder, Major | Phase 2 | Completed | Boehringer Ingelheim | 225 | 2024-10-01 | 2026-05-22 |
| Efficacy of MI078 Capsules in Treating Postpartum Depression MI078 capsule dose 1, MI078 capsule dose 2, placebo - Postpartum Depression | Phase 2 | Completed | Nanjing Minova Pharmaceutical Co., Ltd. | 72 | 2024-09-09 | 2026-06-25 |
| Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) BHV-7000 - Major Depressive Disorder | Phase 2 | Completed | Biohaven Therapeutics Ltd. | 233 | 2024-08-01 | 2026-10-14 |
| Psilocybin for Treatment-Resistant Depression Psilocybin 25mg, Placebo (active placebo) - Major Depressive Disorder, Anhedonia | Phase 2 | Completed | University of Colorado, Denver | 20 | 2024-07-08 | 2026-05-22 |
| RE104 Safety and Efficacy Study in Postpartum Depression RE104 for Injection - Postpartum Depression | Phase 2 | Completed | Reunion Neuroscience Inc | 84 | 2024-06-14 | 2026-05-14 |
| Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression BHV-7000, Placebo - Major Depressive Disorder | Phase 2 | Completed | Biohaven Therapeutics Ltd. | 336 | 2024-05-28 | 2026-10-14 |
| BHV-7000 Acute Treatment of Bipolar Mania BHV-7000, Placebo - Bipolar Disorder | Phase 2 / Phase 3 | Completed | Biohaven Therapeutics Ltd. | 274 | 2024-05-28 | 2025-12-16 |
| To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder. NMRA-335140 80 mg, Placebo - Major Depressive Episode Associated With Bipolar II Disorder | Phase 2 | Completed | Neumora Therapeutics, Inc. | 18 | 2024-05-13 | 2026-03-30 |
Showing 20 of 529. Sign in to see all of them.
Depressive Disorder, Major (326) · Depression (196) · Bipolar Disorder (115) · Depressive Disorder (76) · Depressive Disorder, Treatment-Resistant (42) · Anxiety Disorders (24) · Depression, Postpartum (22) · Mental Disorders (22) · Psychotic Disorders (22) · Mania (15) · Schizophrenia (15) · Dysthymic Disorder (13) · Alcoholism (11) · Anhedonia (7)
Mental Disorders (507) · Depressive Disorder (341) · Behavior (212) · Behavioral Symptoms (198) · Bipolar and Related Disorders (115) · Pathological Conditions, Signs and Symptoms (52) · Nervous System Diseases (44) · Signs and Symptoms (40) · Neurologic Manifestations (33) · Neurobehavioral Manifestations (25) · Schizophrenia Spectrum and Other Psychotic Disorders (25) · Urogenital Diseases (25) · Female Urogenital Diseases and Pregnancy Complications (23) · Chemically-Induced Disorders (22)
Ketamine (26) · Escitalopram (20) · Sertraline (15) · Psilocybin (14) · Transcranial Direct Current Stimulation (13) · Venlafaxine Hydrochloride (12) · Citalopram (11) · Therapeutics (11) · Cognitive Behavioral Therapy (10) · Fluoxetine (10) · Bupropion (9) · Vortioxetine (8) · Midazolam (7) · Paroxetine (7) · Transcranial Magnetic Stimulation (7)
National Institute of Mental Health (NIMH) (21) · GlaxoSmithKline (14) · Janssen Research & Development, LLC (12) · Massachusetts General Hospital (12) · New York State Psychiatric Institute (10) · University of Pittsburgh (10) · Forest Laboratories (7) · H. Lundbeck A/S (7) · Medical University of South Carolina (7) · Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · The University of New South Wales (7) · Alto Neuroscience (6) · Mclean Hospital (6) · Sanofi (6) · University of Sao Paulo (6)
United States (352) · Canada (45) · Germany (32) · Poland (23) · Australia (22) · Russia (22) · United Kingdom (20) · Japan (18) · Bulgaria (16) · China (15) · Spain (13) · Ukraine (13) · Finland (12) · France (11) · Slovakia (11)
Maurizio Fava, MD (6) · Carlos A Zarate, M.D. (4) · Andre R Brunoni, MD (3) · Andrew A Nierenberg, MD (3) · Beth L Murphy, MD, PhD (3) · Ihsan M Salloum, MD, MPH (3)
PMID 34510411, PMID 23146246, PMID 27685842, PMID 28086004, PMID 30508090, PMID 31270774, PMID 31969269, PMID 32785636, PMID 32792252, PMID 33128208, PMID 34131914, PMID 34623633, PMID 34817851, PMID 35092868, PMID 37585253, PMID 39240566, PMID 39955416, PMID 40398609, PMID 42304135, PMID 42521762, PMID 42560883, PMID 10197825, PMID 12113998, PMID 12217271, PMID 14557145, PMID 15365580, PMID 15580167, PMID 15583115, PMID 15630071, PMID 15982444, PMID 16319710, PMID 16390366, PMID 16491981, PMID 16894061, PMID 17012684, PMID 17215046, PMID 17690799, PMID 17897484, PMID 18061147, PMID 18295436, PMID 18314433, PMID 18457236, PMID 18480694, PMID 18762591, PMID 18996507, PMID 19182688, PMID 19192466, PMID 19223438, PMID 19254438, PMID 19321268
2015 (5), 2016 (3), 2019 (3), 2008 (2), 2017 (2), 2018 (2), 2023 (2), R33MH122464 (2), U54DA036114 (2), 2009 (1), 2014 (1), 271201100006I-0-27100007-1 (1), K23DA015440 (1), K23MH064528 (1), K23MH066265 (1)